Explore recent issues of Contract Pharma covering key industry trends.
Read the full digital version of our magazine online.
Behind every facility expansion, technology investment, and quality milestone in the CDMO sector is a leadership team making deliberate choices about where to focus, how to grow, and when to take calculated risks.
Stay informed! Subscribe to Contract Pharma for industry news and analysis.
Get the latest updates and breaking news from the pharmaceutical and biopharmaceutical industry.
Discover the newest partnerships and collaborations within the pharma sector.
Keep track of key executive moves and promotions in the pharma and biopharma industry.
Updates on the latest clinical trials and regulatory filings.
Stay informed with the latest financial reports and updates in the pharma industry.
Expert Q&A sessions addressing crucial topics in the pharmaceutical and biopharmaceutical world.
In-depth articles and features covering critical industry developments.
Access exclusive industry insights, interviews, and in-depth analysis.
Insights and analysis from industry experts on current pharma issues.
A one-on-one video interview between our editorial teams and industry leaders.
Listen to expert discussions and interviews in pharma and biopharma.
A detailed look at the leading US players in the global pharmaceutical and BioPharmaceutical industry.
Browse companies involved in pharmaceutical manufacturing and services.
Comprehensive company profiles featuring overviews, key statistics, services, and contact details.
A comprehensive glossary of terms used in the pharmaceutical and biopharmaceutical industry.
Watch in-depth videos featuring industry insights and developments.
Download in-depth eBooks covering various aspects of the pharma industry.
Access detailed whitepapers offering analysis on industry topics.
View and download brochures from companies in the pharmaceutical sector.
Explore content sponsored by industry leaders, providing valuable insights.
Stay updated with the latest press releases from pharma and biopharma companies.
Explore top companies showcasing innovative pharma solutions.
Meet the leaders driving innovation and collaboration.
Engage with sessions and panels on pharma’s key trends.
Hear from experts shaping the pharmaceutical industry.
Join online webinars discussing critical industry topics and trends.
A comprehensive calendar of key industry events around the globe.
Live coverage and updates from major pharma and biopharma shows.
Find advertising opportunities to reach your target audience with Contract Pharma.
Review the editorial standards and guidelines for content published on our site.
Understand how Contract Pharma handles your personal data.
View the terms and conditions for using the Contract Pharma website.
What are you searching for?
Tambe becomes the first CEO of Biocon Limited following the full integration of Biocon Biologics as its wholly owned subsidiary.
March 27, 2026
By: Patrick Lavery
Content Marketing Editor
Biocon is appointing Shreehas Tambe as Chief Executive Officer (CEO) and Managing Director effective April 1, 2026. Tambe is the first CEO of Biocon Limited, following the full integration of Biocon Biologics as its wholly owned subsidiary.
In its revamped structure, Biocon’s portfolio includes biosimilars, insulins, complex generics, and peptides, spanning diabetes, obesity, oncology, and immunology.
Despite the new appointment, Tambe is not new to the company nor his roles. Prior to this announcement, he had held the same titles with Biocon Biologics, with notable success. Biocon says its $5.5 billion revenue valuation as of 2025 makes it one of the world’s top five biosimilar companies.
Tambe oversaw the acquisition of Biocon’s biosimilars business, supervising its consolidation and creating a fully integrated lab-to-patient experience. Now, he will lead Biocon’s combined platform of biosimilars and generics, strengthening abilities to operate at scale and compete globally.
“It is an honor and privilege to lead Biocon at such a pivotal moment,” Tambe said. “Biocon is among the few organizations that have transformed access to life-saving treatments by effectively leveraging science and technology … My focus will be on strengthening our foundation, consolidating our business, and accelerating sustainable growth.”
“Shreehas brings deep scientific expertise, strategic rigor, and a steadfast commitment to advancing affordable healthcare,” said Executive Chairperson Kiran Mazumdar-Shaw. “I am confident he will drive disciplined execution and translate our scale into sustained global leadership.”
In a related move, Siddharth Mittal will transition to a new leadership role in the Biocon Group, as yet undisclosed. Mittal joined Biocon in 2013 and served as Chief Financial Officer, then CEO and Managing Director.
Also, Kedar Upadhye is Biocon Limited’s new Chief Financial Officer.
Headquartered in India, Biocon operates in more than 120 countries and has a workforce of more than 9500.
Enter the destination URL
Or link to existing content
Enter your account email.
A verification code was sent to your email, Enter the 6-digit code sent to your mail.
Didn't get the code? Check your spam folder or resend code
Set a new password for signing in and accessing your data.
Your Password has been Updated !